Multiple sclerosis. Multiple sclerosis
Conditions
Interventions
Intervention 1: Intervention group: memantine, 10 mg oral tablet, one per day for the first week and then twice a day for three months. Intervention 2: Control group: placebo (exactly the same as the
Treatment - Drugs
Intervention group: memantine, 10 mg oral tablet, one per day for the first week and then twice a day for three months
Control group: placebo (exactly the same as the intervention group), oral tablet, one per day for the first week and then twice a day for three months
Sponsors
Iranian Center of Neurological Research
Eligibility
Sex/Gender
All
Age
20 Years to 55 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: A history of multiple sclerosis (MS) for more than one year; Type of MS was Relapsing Remitting (RR); Subjective fatigue (grade 3 or 4 fatigue based on questionnaires); Age of 20-55 years; Expanded Disability Status Scale (EDSS): 0-5; Consent to participate in the study. Exclusion criteria: Use of Modafinil, Ritalin or Amantadine; A history of seizure and kidney disease; Taking selective serotonin reuptake inhibitors (SSRI); Other types of diseases.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fatigue. Timepoint: before intervention, 3 months after start of intervention. Method of measurement: MFIS Questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Depression. Timepoint: before intervention, 3 months after start of intervention. Method of measurement: Beck II questionnaire.;Cognitive disorders. Timepoint: before intervention, 3 months after start of intervention. Method of measurement: MACFIMS test.;Disability. Timepoint: before intervention, 3 months after start of intervention. Method of measurement: EDSS test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammad hossein Harirchian
Iranian Center of Neurological Research
Outcome results
None listed